The World Health Organization (WHO) has further delayed the emergency use authorisation (EUA) for Covaxin, the Covid vaccine developed in India, as the global body has sent more technical to its manufacturer Bharat Biotech, according to sources. This setback is likely to adversely affect Indians', especially students', international travel plans.